169 related articles for article (PubMed ID: 24618438)
1. Biomarkers in pancreatic neuroendocrine tumors.
Theochari MS; Syrigos KN; Saif MW
JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
3. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
Batukbhai BDO; De Jesus-Acosta A
Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
[TBL] [Abstract][Full Text] [Related]
4. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.
Roland CL; Starker LF; Kang Y; Chatterjee D; Estrella J; Rashid A; Katz MH; Aloia TA; Lee JE; Dasari A; Yao JC; Fleming JB
Surgery; 2017 Mar; 161(3):753-759. PubMed ID: 27816207
[TBL] [Abstract][Full Text] [Related]
5. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
6. SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors.
Hofving T; Elias E; Rehammar A; Inge L; Altiparmak G; Persson M; Kristiansson E; Johansson ME; Nilsson O; Arvidsson Y
BMC Cancer; 2021 Jan; 21(1):101. PubMed ID: 33509126
[TBL] [Abstract][Full Text] [Related]
7. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
[TBL] [Abstract][Full Text] [Related]
8. Expression of p27
Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
[TBL] [Abstract][Full Text] [Related]
9. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
Nieveen van Dijkum EJM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
[No Abstract] [Full Text] [Related]
10. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G; La Rosa S
Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in neuroendocrine tumors.
Duque M; Modlin IM; Gupta A; Saif MW
JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor.
Shin JU; Lee CH; Lee KT; Lee JK; Lee KH; Kim KM; Kim KM; Park SM; Rhee JC
Tumour Biol; 2012 Oct; 33(5):1645-51. PubMed ID: 22707287
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
[TBL] [Abstract][Full Text] [Related]
15. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
17. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.
Miki M; Oono T; Fujimori N; Takaoka T; Kawabe K; Miyasaka Y; Ohtsuka T; Saito D; Nakamura M; Ohkawa Y; Oda Y; Suyama M; Ito T; Ogawa Y
Cancer Med; 2019 Jul; 8(8):3748-3760. PubMed ID: 31129920
[TBL] [Abstract][Full Text] [Related]
18. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
19. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
